Ami Organics Limited, a leading global manufacturer of advance pharmaceutical intermediates and speciality chemicals, today announced financial results for the first quarter ended June 30, 2024.

Ami Organics posted 14.9 per cent rise in its Q1 FY25 revenue from operations at Rs. 176.7 crore as compared to Rs. 153.7 crore in Q1 FY24. The company posted revenue from operations Rs. 225 crore during Q4 FY24.

The company posted net profit of Rs. 14.7 crore in Q1 FY25 as compared to Rs. 22.2 crore in Q1 FY24, reflecting a drop of 33.9 per cent. The net profit dropped by 42.8 per cent when compared to Q4 FY24. PAT margin for the quarter was 8.3%. PAT margins were impacted due to higher finance cost as well as higher depreciation cost.

EBITDA for Q1 FY25 at Rs. 29.5 crore is down 13.2 per cent YoY compared to Rs. 34 crore in Q1FY24. EBITDA margin for the quarter was at 16.7 per cent as compared to 22.1 per cent in Q1FY24. EBITDA margins contracted due to lower gross margins coupled with higher employee expenses led by annual increments as well as new hiring for Ankleshwar plant.

Commenting on results, Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited, said: “I am pleased to report that we continue to successfully navigate the challenging industry landscape, achieving strong revenue of Rs.176 crore, which represents a 14.9% year-over-year growth. This growth was primarily driven by our core pharmaceutical business, while the specialty chemicals segment saw a modest 10% increase.

“During the quarter, we also successfully completed the Good Manufacturing Practices (GMP) inspection by the Pharmaceutical and Medical Devices Agency (PMDA), Japan, with no critical or major observations. To our knowledge, we may be the only company in India to have successfully passed both USFDA and PMDA inspections in the advanced pharmaceutical intermediate sector.

“Historically, Q1 is always lowest quarter in terms of revenue each financial year since inception, and we typically see sequential growth from Q1 to Q4. I anticipate similar strong sequential growth in the coming quarters. Looking at our current order book, I am confident that we will comfortably meet our 25% growth guidance for the year.”